http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021308232-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_044f0458e9a683d611f9c14ea051cd94
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y115-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
filingDate 2021-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9639536868c43a8a37dd434291b53447
publicationDate 2021-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021308232-A1
titleOfInvention Treatement of pathogen infections formulations and methods for use
abstract An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus.
priorityDate 2020-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011274680-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87133406
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226919707

Total number of triples: 37.